On February 13, Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative allogeneic chimeric antigen receptor (CAR) T-cell therapy ...

Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During their preparation for this battle, B cells transiently revert to a more ...

New study demonstrates how high-affinity B cells 'bank' their best traits instead of rolling the dice and risking deleterious mutations, with implications for better vaccine design. A vaccine's ...

Scientists analyzing human and mouse pancreatic lymph nodes (PLNs) and spleens have identified a distinct subset of CD4 memory helper T cells associated with type 1 diabetes (T1D). Reported by ...

B-PLL is a rare subtype that’s more aggressive than other blood cancers and has a low survival rate. However, ongoing research and clinical trials may offer new treatment options to improve outcomes.

Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma. Treatment with cemacabtagene ansegedleucel (cema-cel) ...

Four symptoms may indicate a possible relapse of diffuse large B-cell lymphoma. Learn more about them and when to contact a doctor. A relapse of diffuse large B-cell lymphoma can cause a variety of ...